Drug sensitivity prediction by CpG island methylation profile in the NCI-60 cancer cell line panel

Cancer Research

Volumn 67, Issue 23, 2007, Pages 11335-11343

  Shen, Lanlan ^a,c   Kondo, Yutaka ^b   Ahmed, Saira ^a   Boumber, Yanis ^a   Konishi, Kazuo ^a   Guo, Yi ^a   Chen, Xinli ^a   Vilaythong, Jill N ^a   Issa, Jean Pierre J ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; BISULFITE; GUANINE; PROTEIN P53; PROTEIN P73; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CPG ISLAND; DATA BASE; DNA METHYLATION; DRUG SENSITIVITY; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; KIDNEY CANCER; MELANOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CISPLATIN; CPG ISLANDS; DNA METHYLATION; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG TOLERANCE; EPIGENESIS, GENETIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; MELANOMA; NUCLEAR PROTEINS; POLYMERASE CHAIN REACTION; PROMOTER REGIONS (GENETICS); RNA, MESSENGER; TUMOR SUPPRESSOR PROTEINS;

EID: 37049001640     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-1502     Document Type: Article

References (49)

1. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006;6:813-23.
2. Weinstein JN. Integromic analysis of the NCI-60 cancer cell lines. Breast Dis 2004;19:11-22.
3. Staunton JE, Slonim DK, Coller HA, et al. Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci U S A 2001;98:10787-92.
4. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Advances in Cancer Research 1998;72:141-96.
5. Cedar H, Solage A, Glaser G, Razin A. Direct detection of methylated cytosine in DNA by use of the restriction enzyme Mspi. Nucleic Acids Research 1979;6:2125-32.
6. Jones PA, Laird PW. Cancer epigenetics comes of age. Nature Genetics 1999;21:163-7.
7. Issa JP. DNA methylation in the treatment of hematologic malignancies. Clin Adv Hematol Oncol 2005;3:684-6.
8. Issa JPJ, Baylin SB, Belinsky SA. Methylation of the estrogen receptor CpG island in lung tumors is related to the specific type of carcinogen exposure. Cancer Research 1996;56:3655-8.
9. Li Q, Kopecky KJ, Mohan A, et al. Estrogen receptor methylation is associated with improved survival in adult acute myeloid leukemia. Clinical Cancer Research 1999;5:1077-84.
10. Agrelo R, Cheng WH, Setien F, et al. Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer. Proc Natl Acad Sci U S A 2006;103:8822-7.
11. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343:1350-4.
12. Satoh A, Toyota M, Itoh F, et al . Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer. Cancer Res 2003;63:8606-13.
13. Clark SJ, Harrison J, Paul CL, Frommer M. High-sensitivity mapping of methylated cytosines. Nucleic Acids Research 1994;22:2990-7.
14. Xiong ZG, Laird PW. COBRA: A sensitive and quantitative DNA methylation assay. Nucleic Acids Research 1997;25:2532-4.
15. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996;93:9821-6.
16. Ahuja N, Li Q, Mohan AL, Baylin SB, Issa JPJ. Aging and DNA methylation in colorectal mucosa and cancer. Cancer Research 1998;58:5489-94.
17. Boumber YA, Kondo Y, Chen X, et al. RIL, a LIM gene on 5q31, is silenced by methylation in cancer and sensitizes cancer cells to apoptosis. Cancer Res 2007;67:1997-2005.
18. Burbee DG, Forgacs E, Zochbauer-Muller S, et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 2001;93:691-9.
19. Colella S, Shen L, Baggerly KA, Issa JPJ, Krahe R. Sensitive and quantitative universal Pyrosequencing (TM) methylation analysis of CpG sites. Biotechniques 2003;35:146-50.
20. Corn PG, Kuerbitz SJ, van Noesel MM, et al. Transcriptionalsil encing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5′ CpG island methylation. Cancer Research 1999;59:3352-6.
21. Corn PG, Smith BD, Ruckdeschel ES, Douglas D, Baylin SB, Herman JG. E-cadherin expression is silenced by 5′ CpG island methylation in acute leukemia. Clinical Cancer Research 2000;6:4243-8.
22. Du Y, Carling T, Fang W, Piao Z, Sheu JC, Huang S. Hypermethylation in human cancers of the RIZ1 tumor suppressor gene, a member of a histone/protein methyltransferase superfamily. Cancer Res 2001;61:8094-9.
23. Esteller M, Corn PG, Urena JM, Gabrielson E, Baylin SB, Herman JG. Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. Cancer Research 1998;58:4515-8.
24. Kondo Y, Shen L, Yan PS, Huang THM, Issa JPJ. Chromatin immunoprecipitation microarrays for identification of genes silenced by histone H3 lysine 9 methylation. Proc Natl Acad Sci U S A 2004;101:7398-403.
25. Murai M, Toyota M, Satoh A, et al. Aberrant DNA methylation associated with silencing BNIP3 gene expression in haematopoietic tumours. Br J Cancer 2005;92:1165-72.
26. Shen L, Kondo Y, Hamilton SR, Rashid A, Issa JPJ. p14 methylation in human colon cancer is associated with microsatellite instability and wild-type p53. Gastroenterology 2003;124:626-33.
27. Shen L, Kondo Y, Rosner GL, et al. MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst 2005;97:1330-8.
28. Shen LL, Toyota M, Kondo Y, et al. Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia. Blood 2003;101:4131-6.
29. Toyota M, Issa JPJ. CpG island methylator phenotypes in aging and cancer. Semin Cancer Biol199 9;9:349-57.
30. Toyota M, Shen L, Ohe-Toyota M, Hamilton SR, Sinicrope FA, Issa JPJ. Aberrant methylation of the cyclooxygenase 2 CpG island in colorectal tumors. Cancer Research 2000;60:4044-8.
31. Virmani AK, Rathi A, Zochbauer-Muller S, et al. Promoter methylation and silencing of the retinoic acid receptor-β gene in lung carcinomas. J Natl Cancer Inst 2000;92:1303-7.
32. Scherf U, Ross DT, Waltham M, et al. A gene expression database for the molecular pharmacology of cancer. Nat Genet 2000;24:236-44.
33. Paull KD, Shoemaker RH, Hodes L, et al. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 1989;81:1088-92.
34. Weinstein JN, Kohn KW, Grever MR, et al. Neural computing in cancer drug development: predicting mechanism of action. Science 1992;258:447-51.
35. Marin MC, Jost CA, Irwin MS, DeCaprio JA, Caput D, Kaelin WG, Jr. Viral oncoproteins discriminate between p53 and the p53 homolog p73. Mol Cell Biol 1998;18:6316-24.
36. Irwin MS, Kondo K, Marin MC, Cheng LS, Hahn WC, Kaelin WG, Jr. Chemosensitivity linked to p73 function. Cancer Cell 2003;3:403-10.
37. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science 1991;251:1451-5.
38. Lee WH, Morton RA, Epstein JI, et al. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci U S A 1994;91:11733-7.
39. Chang MS, Uozaki H, Chong JM, et al. CpG island methylation status in gastric carcinoma with and without infection of Epstein-Barr virus. Clin Cancer Res 2006;12:2995-3002.
40. Nass SJ, Herman JG, Gabrielson E, et al. Aberrant methylation of the estrogen receptor and E-cadherin 5′ CpG islands increases with malignant progression in human breast cancer. Cancer Res 2000;60:4346-8.
41. Uhlmann K, Rohde K, Zeller C, et al. Distinct methylation profiles of glioma subtypes. Int J Cancer 2003;106:52-9.
42. Henrique R, Jeronimo C. Molecular detection of prostate cancer: a role for GSTP1 hypermethylation. Eur Urol200 4;46:660-9.
43. Bauman GS, Ino Y, Ueki K, et al. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int J Radiat Oncol Biol Phys 2000;48:825-30.
44. Yuan ZM, Shioya H, Ishiko T, et al. p73 is regulated by tyrosine kinase c-Ablin the apoptotic response to DNA damage. Nature 1999;399:814-7.
45. Bellacosa A. Functional interactions and signaling properties of mammalian DNA mismatch repair proteins. Cell Death Differ 2001;8:1076-92.
46. De LV, Costanzo A, Barcaroli D, et al. Two new p73 splice variants, γ and δ, with different transcriptional activity. J Exp Med 1998;188:1763-8.
47. Zhu J, Jiang J, Zhou W, Chen X. The potential tumor suppressor p73 differentially regulates cellular p53 target genes. Cancer Res 1998;58:5061-5.
48. Stiewe T, Putzer BM. Role of p73 in malignancy: tumor suppressor or oncogene? Cell Death Differ 2002;9:237-45.
49. Vikhanskaya F, Marchini S, Marabese M, Galliera E, Broggini M. P73a overexpression is associated with resistance to treatment with DNA-damaging agents in a human ovarian cancer cell line. Cancer Res 2001;61:935-8.